Ipamorelin 10mg research peptide is the advanced-format GHS-R1a selective GHRP for established UK laboratory programmes requiring full dose-response gradients and multi-arm study designs. ≥98% purity. Janoshik tested. Same-day UK dispatch before 4pm. For research use only.
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
IPAMORELIN 10mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
Ipamorelin 10 mg:
Click Here To View
Research use only • UK dispatch • Orders before 4pm ship same day • Secure checkout
Ipamorelin 10mg Research Peptide UK
Ipamorelin 10mg is the advanced-format version of the most receptor-selective GHRP in the UK research peptide market. Identical compound to Ipamorelin 5mg in every respect — synthetic pentapeptide, C38H49N9O5, molecular weight 711.85 g/mol, selective GHS-R1a agonist — but providing the compound volume required for full dose-response concentration gradients, multi-arm experimental designs, and extended single-batch longitudinal studies may be less practical for some extended experimental designs.
The research case for the ipamorelin 10mg format builds on programme maturity. Once the 5mg pilot phase has validated assay conditions, confirmed receptor response, and established the experimental design, the 10mg format provides consistent compound supply across multiple arms or extended time points without the inter-batch variability that comes from sourcing multiple 5mg vials. For first-time ipamorelin research and a complete guide to the mechanism of action, see the ipamorelin 5mg research guide on the Ascend Peptides UK blog, which covers both formats in detail.
Ipamorelin 10mg is the standard GHRP format in the most widely studied GHRH and GHRP combined research protocol. When paired with CJC-1295 Without DAC 10mg, these two compounds target mechanistically distinct receptors — ipamorelin at GHS-R1a and CJC-1295 at GHRHR. The two compounds target distinct receptor pathways that have been explored separately in experimental literature. Each operates through a distinct molecular entry point, allowing them to function as independent variables within the same experimental system.
For researchers studying downstream effects of GH axis stimulation, IGF-1 LR3 1mg provides the growth factor research tool for the downstream GH-IGF-1 signalling cascade, operating through the IGF-1 receptor (IGF-1R) rather than the ghrelin or GHRH receptor pathways. This mechanistic non-overlap means all three compounds can be incorporated into the same multi-compound protocol without pathway interference.
All ipamorelin 10mg batches are independently tested by Janoshik. HPLC purity confirmed at greater than or equal to 98%. LC-MS confirms C38H49N9O5 at 711.85 g/mol. Batch-specific Certificate of Analysis available for independent verification.
For laboratory handling purposes, the lyophilised material may be reconstituted using bacteriostatic water or another suitable buffered aqueous solution depending on analytical protocol requirements. Store lyophilised material at -20°C and avoid repeated freeze-thaw cycles.
WADA Status: Ipamorelin-related compounds appear on the WADA Prohibited List.
DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.
A curated entry point for buyers comparing quality, documentation, and availability.
UK same-day dispatch – PCI-
compliant payments –
Laboratory research only
© 2026 by Ascend Peptides Uk.
